Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128953 | 0.87 | P2RX7 (0.37) | P2RX7SMN1; SMN2CNR1HSD11B1SLC16A3 | |
| SCHEMBL3708990 | 0.85 | P2RX7 (0.39) | P2RX7SMN1; SMN2CNR1SLC16A3SLC16A1 | |
| SCHEMBL4127317 | 0.83 | NOTUM (0.36) | P2RX7TMEM97SIGMAR1SLC16A3SLC16A1 | |
| SCHEMBL2838664 | 0.83 | SMN1; SMN2 (0.38) | P2RX7SMN1; SMN2CNR1HSD11B1SLC16A3 | |
| SCHEMBL4134986 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2CNR1SLC16A3SLC16A1MAPT | |
| SCHEMBL4119116 | 0.82 | ATM (0.35) | P2RX7CNR1POLBMAPTTP53 | |
| SCHEMBL4120313 | 0.82 | MDM2 (0.38) | P2RX7SMN1; SMN2POLBMAPTTP53 | |
| SCHEMBL4135340 | 0.81 | CNR1 (0.36) | P2RX7CNR1HSD11B1SLC16A3SLC16A1 | |
| SCHEMBL4140877 | 0.81 | SLC16A3 (0.38) | P2RX7SMN1; SMN2CNR1SLC16A3SLC16A1 | |
| SCHEMBL4126825 | 0.80 | P2RX7 (0.36) | P2RX7SMN1; SMN2CNR1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | P2RX7 1303/4885SMN1; SMN2 4327/4885CNR1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.